The group's production base is located at the foot of the beautiful Changbai Mountain, covering an area of ??42,000 square meters, with a construction area of ??21,000 square meters, and an annual production capacity of 4 billion tablets (capsules). The group has 8 world-class production lines for tablets, capsules, and ointments; one Class I new drug and two Class II new drugs with independent intellectual property rights; one Class I new drug and four Class III new drugs under development; it has obtained U.S. , Germany, France, the United Kingdom, Canada, and Australia have two foreign patented new drugs, forming a drug structure for the treatment of hypertension, hyperlipidemia, and hyperglycemia.
Shi Huida Pharmaceutical Group attaches great importance to talents and fully implements the talent strategy, achieving leap-forward sustainable development of the enterprise. The group has a high-quality team, composed of 26 experts and an academic advisory group, with nearly 1,000 key managers and technical personnel, 93 of whom have college or technical secondary school education, 76 of whom have doctorates, masters and other professional and technical personnel, and 19 of whom have intermediate professional titles or above. . The Group has established long-term scientific research cooperation relationships with many well-known scientific research institutions such as Peking University, Shanghai Jiao Tong University, and Huazhong University of Science and Technology, and has undertaken the “211 Project” of the National Ministry of Education, the “Eleventh Five-Year Plan” project of the National Ministry of Health and the Ministry of Science and Technology, and the National The Ministry of Science and Technology’s “863” project has published nearly 600 academic articles.
The company actively repays society and has invested nearly 100 million yuan to establish the "Shi Huida Research Fund" to support national scientific research. It also established the "Shi Huida Relief Fund" to support the construction of disaster areas, rescue children with congenital heart disease, and established the "Shi Huida Relief Fund". Education Fund" supports the Chen Yun Education Fund to help poor children and minority children go to school.
In order to promote the rapid development of the country’s pharmaceutical industry, companies have recruited domestic scientific research talents to actively strive to develop independently innovative biological drugs, chemical drugs, modern traditional Chinese medicine and health care drug products. After 2-3 years of hard work, the company will There are 3-4 Class I new drugs on the market, forming a series of drugs for the treatment of hypertension, hyperlipidemia, hyperglycemia and health care, which will make more contributions to national drug reform and people's health.
In 2012, Shi Huida achieved an output value of 1.85 billion yuan, sales exceeded 1.3 billion yuan, and taxes paid were 194 million yuan. Compared with similar imported drugs, it has saved the country and patients nearly 10 billion yuan in drug costs. By 2015, it can achieve sales revenue of 2 billion yuan and pay taxes of 400 million yuan. Created the miracle of national innovative medicine. According to authoritative statistics from IMS Corporation of the United States and Southern Intelligence, Shihuida ranks first in both sales volume and retail sales of antihypertensive drugs in Chinese hospitals. It is the only Chinese drug to enter the top ten. Shihuida Pharmaceutical ranked first in the national pharmaceutical company rankings in 2012. Ranked first in Jilin Province in terms of revenue from its main business of chemical drugs